NICE: Roche invited to submit CDF proposal for atezolizumab

NICE: Roche invited to submit CDF proposal for atezolizumab PharmacoEconomics & Outcomes News 784, p35 - 12 Aug 2017 NICE: Roche invited to submit CDF proposal for atezolizumab NICE has asked Roche to submit a Cancer Drugs Fund (CDF) proposal for the immunotherapy drug, atezolizumab [Tecentriq], for advanced urothelial cancer. The invitation came after NICE’s earlier assessment found stronger evidence is needed to show the drug is both clinically and cost effective. Including the drug in the CDF means patients can access the treatment while the company gathers more data. Commenting on the draft appraisal, Director of the Centre for Health Technology Evaluation at NICE, Professor Carole Longson noted "there is a lack of new treatment options for people who have advanced urothelial cancer, so I am very disappointed we’ve not been able to recommend atezolizumab at this stage . . . I hope Roche will work with us to submit a CDF proposal. Funding through the CDF means it could be offered to patients who cannot undergo chemotherapy while we collect more evidence. This will be a positive step for a lot of people". NICE. Roche invited to submit a CDF proposal for urothelial cancer drug. Internet Document : 2 Aug 2017. Available from: URL: article/roche-invited-to-submit-a-cdf-proposal-for-urothelial-cancer- drug 803263082 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 PharmacoEconomics & Outcomes News Springer Journals

NICE: Roche invited to submit CDF proposal for atezolizumab

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial